FHA
AKBA icon

First Horizon Advisors’s Akebia Therapeutics AKBA Stock Holding History

First Horizon Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,600
Closed -$5.12K – 2389
2023
Q2 		$5.12K Buy
+5,600
New +$5.41K ﹤0.01% 1782
2021
Q4 		– Sell
-63
Closed – – 2247
2021
Q3 		$0 Buy
+63
New +$180 ﹤0.01% 2267

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

First Horizon Advisors's AKBA Position: Q3 2023 in Review

First Horizon Advisors sold out of Akebia Therapeutics (AKBA) in Q3 2023, closing a stake of 5,600 shares — an estimated $5.12K sold.

First Horizon Advisors first reported a position in AKBA in Q3 2021 and held it in 2 quarters. The position peaked at $5.12K in Q2 2023. 76 funds tracked by Wall St. Rank hold AKBA as of Q3 2023.

  • First Horizon Advisors reported no remaining Akebia Therapeutics position as of Q3 2023 after selling out during the quarter.
  • First Horizon Advisors sold 5,600 Akebia Therapeutics shares in Q3 2023, an estimated $5.12K.
  • First Horizon Advisors first reported a position in Akebia Therapeutics in Q3 2021 and held it in 2 quarters.
  • First Horizon Advisors's Akebia Therapeutics position peaked at $5.12K in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2023.

Based on First Horizon Advisors's 13F filing for Q3 2023, filed 27 Oct 2023.